Across TCGA pan-cancer cohorts, CD3E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD3E data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD3E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD3E expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, UCEC, and SKCM are the cancer types where CD3E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.122	0.696	<.001	45	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.683	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CD3E tumor-vs-normal RNA expression · all CD3E data types